tradingkey.logo

COSCIENS Biopharma Inc

CSCI
2.720USD
0.0000.00%
종가 02/06, 16:00ET시세는 15분 지연됩니다
8.64M시가총액
손실P/E TTM

COSCIENS Biopharma Inc

2.720
0.0000.00%

자세한 내용은 COSCIENS Biopharma Inc 회사

COSCIENS Biopharma Inc., formerly Aeterna Zentaris Inc., is a specialty biopharmaceutical company engaged in the development and commercialization of a diverse portfolio of pharmaceutical and diagnostic products, including those focused on areas of unmet medical need. Its lead product, macimorelin (Macrilen; Ghryvelin), is an oral test indicated for the diagnosis of adult growth hormone deficiency (AGHD). The Company is also engaged in the development of therapeutic assets and proprietary extraction technology, which is applied to the production of active ingredients from renewable plant resources used in cosmeceutical products (i.e., oat beta glucan and avenanthramides, which are found in skincare product brands like Aveeno and Burt’s Bees formulations) and being developed as potential nutraceuticals and/or pharmaceuticals.

COSCIENS Biopharma Inc 정보

종목 코드 CSCI
회사 이름COSCIENS Biopharma Inc
상장일Dec 19, 1995
CEOMs. Anna Biehn
직원 수- -
유형Ordinary Share
회계 연도 종료Dec 19
주소C/O Norton Rose Fulbright Canada Llp
도시TORONTO
증권 거래소The Toronto Stock Exchange
국가Canada
우편 번호M5K 1E7
전화18439003201
웹사이트https://www.cosciensbio.com/
종목 코드 CSCI
상장일Dec 19, 1995
CEOMs. Anna Biehn

COSCIENS Biopharma Inc의 회사 임원진

이름
이름/직위
직위
주식 보유
변동
Dr. Ulrich Kosciessa
Dr. Ulrich Kosciessa
Director
Director
1.85K
--
Mr. Robert A. Seager
Mr. Robert A. Seager
Director
Director
--
--
Ms. Nicola Ammer
Ms. Nicola Ammer
Senior Vice President - Clinical Development, Chief Medical Officer
Senior Vice President - Clinical Development, Chief Medical Officer
--
--
Dr. Matthias Gerlach
Dr. Matthias Gerlach
Senior Vice President - Manufacturing and Supply Chain, Managing Director - AEZS Germany
Senior Vice President - Manufacturing and Supply Chain, Managing Director - AEZS Germany
--
--
Mr. Giuliano La Fratta
Mr. Giuliano La Fratta
Chief Financial Officer, Senior Vice President
Chief Financial Officer, Senior Vice President
--
--
Mr. Michel Regnier
Mr. Michel Regnier
Senior Vice President, Chief Technology Officer
Senior Vice President, Chief Technology Officer
--
--
Mr. Ronald W. (Ronnie) Miller
Mr. Ronald W. (Ronnie) Miller
Director
Director
--
--
Mr. Peter H. Puccetti
Mr. Peter H. Puccetti
Chairman of the Board, Interim Chief Executive Officer
Chairman of the Board, Interim Chief Executive Officer
--
--
Mr. David Spear
Mr. David Spear
Director
Director
--
--
Mr. Anthony J. Giovinazzo
Mr. Anthony J. Giovinazzo
Director
Director
--
--
이름
이름/직위
직위
주식 보유
변동
Dr. Ulrich Kosciessa
Dr. Ulrich Kosciessa
Director
Director
1.85K
--
Mr. Robert A. Seager
Mr. Robert A. Seager
Director
Director
--
--
Ms. Nicola Ammer
Ms. Nicola Ammer
Senior Vice President - Clinical Development, Chief Medical Officer
Senior Vice President - Clinical Development, Chief Medical Officer
--
--
Dr. Matthias Gerlach
Dr. Matthias Gerlach
Senior Vice President - Manufacturing and Supply Chain, Managing Director - AEZS Germany
Senior Vice President - Manufacturing and Supply Chain, Managing Director - AEZS Germany
--
--
Mr. Giuliano La Fratta
Mr. Giuliano La Fratta
Chief Financial Officer, Senior Vice President
Chief Financial Officer, Senior Vice President
--
--
Mr. Michel Regnier
Mr. Michel Regnier
Senior Vice President, Chief Technology Officer
Senior Vice President, Chief Technology Officer
--
--

수익 분석

통화: USD마지막 업데이트: Sun, Apr 6
통화: USD마지막 업데이트: Sun, Apr 6
FY2023
FY2022
FY2021
FY2020
FY2019
FY2018
기업이 아직 관련 데이터를 공개하지 않았습니다.
지역별USD
이름
수익
비율
Switzerland
4.32M
95.98%
Ireland
122.00K
2.71%
Other
48.00K
1.07%
Denmark
11.00K
0.24%
사업별
지역별
기업이 아직 관련 데이터를 공개하지 않았습니다.

주식 보유 통계

마지막 업데이트: Thu, Jan 29
마지막 업데이트: Thu, Jan 29
주주
주주 유형
주주
주주
비율
Goodwood Inc.
8.08%
Gagnon (Gilles R)
1.32%
Li (William W. M.D.)
0.08%
Kosciessa (Ulrich)
0.06%
Prefontaine (Stacy)
0.02%
기타
90.44%
주주
주주
비율
Goodwood Inc.
8.08%
Gagnon (Gilles R)
1.32%
Li (William W. M.D.)
0.08%
Kosciessa (Ulrich)
0.06%
Prefontaine (Stacy)
0.02%
기타
90.44%
주주 유형
주주
비율
Investment Advisor/Hedge Fund
8.08%
Individual Investor
1.48%
기타
90.44%

기관 주식 보유

마지막 업데이트: Thu, Jan 1
마지막 업데이트: Thu, Jan 1
보고 기간
기관 수
보유 주식
비율
변동
2025Q4
31
257.31K
8.08%
-38.39K
2025Q3
32
283.56K
8.74%
-15.54K
2025Q2
37
331.27K
10.53%
-6.89K
2025Q1
40
333.44K
10.61%
+29.17K
2024Q4
39
327.35K
8.67%
+13.77K
2024Q3
37
287.99K
7.73%
+16.16K
2024Q2
43
256.95K
8.09%
+189.65K
2024Q1
39
61.15K
4.98%
+40.02K
2023Q4
42
13.03K
1.07%
-9.47K
2023Q3
49
18.14K
1.49%
-6.74K
더 보기

주주 활동

이름
보유 주식
비율
변동
Chg %
날짜
Goodwood Inc.
257.26K
8.08%
--
--
Jun 03, 2025
Gagnon (Gilles R)
41.96K
1.32%
--
--
Mar 26, 2025
Li (William W. M.D.)
2.40K
0.08%
--
--
Mar 26, 2025
Kosciessa (Ulrich)
1.85K
0.06%
--
--
Jun 03, 2025
Prefontaine (Stacy)
767.00
0.02%
+767.00
--
Jun 03, 2024
Osaic Holdings, Inc.
50.00
0%
--
--
Sep 30, 2025
Planning Capital Management Corp
2.00
0%
--
--
Sep 30, 2024
더 보기

관련 ETF

이름
비율
데이터 없음

주식 배당금

지난 5년 동안 총 0.00 USD의 배당금이 분배되었습니다.
날짜
배당금
기준일
지급일
배당락일
데이터 없음

주식 분할

날짜
배당락일
유형
비율
May 01, 2024
Merger
4→1
May 01, 2024
Merger
4→1
May 01, 2024
Merger
4→1
May 01, 2024
Merger
4→1
Jul 19, 2022
Merger
25→1
Jul 19, 2022
Merger
25→1
날짜
배당락일
유형
비율
May 01, 2024
Merger
4→1
May 01, 2024
Merger
4→1
May 01, 2024
Merger
4→1
May 01, 2024
Merger
4→1
Jul 19, 2022
Merger
25→1
Jul 19, 2022
Merger
25→1
Jul 19, 2022
Merger
25→1
Jul 19, 2022
Merger
25→1
KeyAI